Skip to content

China Anti-Rheumatic Drug Market Forecasts Report 2022: A $24.65 Billion Market by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s providing.

China Antirheumatic Medicine Market was valued at US$19.081 billion in 2020. The market is projected to develop at a CAGR of three.73% to achieve a price of US$24.654 billion by 2027.

A rising variety of sufferers affected by arthritis in China is the main driver of the antirheumatic medication market within the nation. In accordance with the info from the Osteoarthritis Analysis Society Worldwide, its 2018 report confirmed that greater than 8 p.c of the Chinese language inhabitants resides with physician-diagnosed symptomatic knee OA, whereas the prevalence of any sort of arthritis/rheumatism was round 32.3 p.c.

As such, altering existence will proceed this pattern through the subsequent 5 years, thus positively impacting the market progress of antirheumatic medication in China. Excessive R&D investments in creating generic medication are additionally a driving issue for the market progress of antirheumatic medication in China.

The nation is the main exporter of generic medication throughout the globe. With a burgeoning middle-class and rapidly-aging society, China’s pharmaceutical business will proceed to develop through the subsequent 5 years, thereby bolstering the antirheumatic medication market progress.

The latest COVID-19 world pandemic outbreak has additionally impacted the expansion of the antirheumatic drug market in China. Pharmaceutical corporations are testing present medication that may successfully deal with signs in sufferers contaminated with this novel coronavirus.

In March 2020, China’s Nationwide Well being Fee accredited Roche’s Actemra to deal with severe coronavirus sufferers with lung injury. The drug is normally for rheumatoid arthritis, first accredited by the US FDA in 2010. With a steady rise within the variety of COVID-19 sufferers, the demand for this drug is rising, thus positively impacting the market progress.

China’s Antirheumatic Medicine market has been segmented primarily based on the kind of illness, sort of molecule, and gross sales channel. By sort of illness, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By sort of molecule, China’s Antirheumatic Medicine market has been categorized into prescription drugs and biopharmaceuticals. The market segmentation has additionally been executed by gross sales channel as prescription and over-the-counter (OTC).

Key Developments within the Market

In March 2022, Adalimumab biosimilar injection (Junmaikang), co-developed by Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd., was accredited by the Chinese language Nationwide Medical Merchandise Administration (NMPA). The Nationwide twelfth 5-12 months Plan for Main New Drug Creation Science and Know-how supplied important scientific and technological help for the event of Junmaikang, which is used to deal with psoriasis, ankylosing spondylitis, and rheumatoid arthritis.

In March 2022, China’s NMPA accredited the usage of GB242 (infliximab) for the therapy of rheumatoid arthritis, Fistulising Crohn’s illness, and Grownup Ulcerative Colitis, amongst few others. With this approval, Chinese language sufferers could have extra various therapy remedy for the therapy of RA.

COVID-19Insights:

COVID-19 had a big impression on China’s antirheumatic medication market. The rising prevalence of rheumatic sufferers led to the elevated demand for medication within the nation.

Nevertheless, the mandated lockdown and social distancing measures resulted within the closure of many manufacturing services and low staffing, slowing down productiveness. The journey restrictions additionally affected the imports and exports in China, creating a spot within the provide and demand chain. The explanations talked about above slowed down the market’s progress.

Key Matters Coated:

1.Introduction

1.1. Market Overview

1.2. COVID-19 Impression

1.3. Market Definition

1.4. Market Segmentation

2.Analysis Methodology

2.1. analysis knowledge

2.2. assumptions

3.Govt Abstract

3.1. Analysis Highlights

4.Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s 5 Forces Evaluation

4.4. Trade Worth Chain Evaluation

5. China Antirheumatic Medicine Market Evaluation, By Sort of Illness

5.1. Introduction

5.2. osteoarthritis

5.3. Rheumatoid Arthritis

5.4. gout

5.5. Lupus

5.6. others

6. China Antirheumatic Medicine Market Evaluation, By Sort of Molecule

6.1. Introduction

6.2. Prescribed drugs

6.3. Biopharmaceuticals

7. China Antirheumatic Medicine Market Evaluation, By Gross sales Channel

7.1. Introduction

7.2. prescription

7.3. Over-The-Counter (OTC)

8. Aggressive Surroundings and Evaluation

8.1. Main Gamers and Technique Evaluation

8.2. Rising Gamers and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9.Firm Profiles

9.1. Pfizer Inc.

9.2. F. Hoffmann-La Roche Ltd

9.3. UCB SA

9.4. Eli Lilly and Firm

9.5. AbbVie Inc.

For extra details about this report go to https://www.researchandmarkets.com/r/6q3w1i

AboutResearchAndMarkets.com

ResearchAndMarkets.com is the world’s main supply for worldwide market analysis studies and market knowledge. We give you the newest knowledge on worldwide and regional markets, key industries, the highest corporations, new merchandise and the newest tendencies.

Leave a Reply

Your email address will not be published. Required fields are marked *